17,261 trials
Mixed Phenotype Acute Leukemia · Previously Treated Myelodysplastic Syndrome · Recurrent Adult Acute Myeloid Leukemia
Primary: Number of Participants Experiencing Dose Limiting Toxicities (DLTs) at the Maximum Tolerated Dose (MTD) for Decitabine When Given Together With G-CLAM Toxicities (DLTs)…
Ovarian Cancer
Primary: Overall Response Rate (ORR) — 1; 10; 5; 2 Participants
Dermatosis Papulosa Nigra
Primary: Physician's DPN Lesions Assessment — -0.75; -1.38; -0.92 score on a scale (PLA)
Metastatic Beast Cancer
Primary: Progression-free Survival (PFS) Rate at 3 Months — 50.1 percent of participants
Metastatic Brain Cancer
Primary: Rate of Deterioration in Neurocognitive Functioning (NF) at Month 12 — 2.8 percentage of participants
Congenital Heart Block · Neonatal Lupus · Autoantibody-Associated Heart Block
Primary: Recurrence of Advanced Heart Block — 5 Participants
Influenza A
Primary: Viral Load AUC (Day 1 to Day 9) by Nasopharyngeal Swab Quantitative PCR — 6.474; 6.974; 11.639 Days*Eq log10 TCID50/mL
Osteosarcoma · Nephrotoxicity · Ototoxicity
Primary: Change in Urinary Biomarkers of Acute Kidney Injury (AKI) Between Pre-Treatment (Baseline), After CISplatin (C) Treatments, and After HDTMX Treatments — 1.7; 1.7; 2.1…
Alcohol Dependence · Post-Traumatic Stress Disorder (PTSD)
Primary: Number of Drinking Days — 46.87; 51.00; 7.44; 17.33 days
Pulmonary Sarcoidosis
Primary: Change Between Baseline and Week 24 in Pulmonary Function as Measured by Spirometry — -1.90; 0.52 Percent Predicted Forced Vital Capacity
Breast Cancer
Primary: Safety of DC Vaccine Combined With Chemotherapy — 10 Participants
Myelodysplastic Syndromes
Primary: Percentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence (TI) Lasting at Least 8 Weeks — 0; 6.1 Percentage of participants
Acute Myeloid Leukemia
Primary: Safety and Tolerability of Treatment as Measured by Incidence of Grade 3-4 Adverse Events Occurring in >5% of Participants — 32; 28; 26; 22 Participants
Heart Failure
Primary: Safety of Cell Delivery — 1; 0 adverse events
Memory Disorders · Multiple Sclerosis
Primary: Change in Memory Change — 0.32; 0.24 z-score